CEBD Coronavirus Dermatology Resource
Journal articles - Implications of coronavirus for use of biologics and other immune modulating therapies
Please see also Guidelines page
Psoriasis management during the COVID-19 pandemic: Recommendations by SIG Psoriasis (IADVL Academy).
Ganguly S, Parthasaradhi A, Thomas J, Arora S, Kumar P, Pradhan S, Saraswat A, Singh V, Komeravalli H.
Indian Dermatol Online J. 2021 Jan 16;12(1):58-65. doi: 10.4103/idoj.IDOJ_685_20. eCollection 2021 Jan-Feb. Review & recommendations.
https://doi.org/10.4103/idoj.idoj_685_20
Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors.
Kridin K, Schonmann Y, Solomon A, Damiani G, Tzur Bitan D, Onn E, Weinstein O, Cohen AD.
J Dermatolog Treat. 2021 Mar 24:1-28. doi: 10.1080/09546634.2021.1905766. Online ahead of print. Cohort study.
https://doi.org/10.1080/09546634.2021.1905766
Comment on "An Evidence-Based Guide to SARS-Cov-2 Vaccination of Patients on Immunotherapies in Dermatology.".
Speeckaert R, Lambert J, Puig L, Speeckaert M, Lapeere H, De Schepper S, van Geel N.
J Am Acad Dermatol. 2021 Mar 17:S0190-9622(21)00584-3. doi: 10.1016/j.jaad.2021.03.038. Online ahead of print. Commentary.
https://doi.org/10.1016/j.jaad.2021.03.038
COVID-19 vaccination and psoriatic patients under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers.
Damiani G, Allocco F; Young Dermatologists Italian Network, Malagoli PO.
Clin Exp Dermatol. 2021 Mar 5. doi: 10.1111/ced.14631. Online ahead of print. Case reports.
https://doi.org/10.1111/ced.14631
Certolizumab pegol in the treatment of psoriasis: Real-life data.
Turkmen M, Dogan S.
Dermatol Ther. 2021 Mar 4:e14929. doi: 10.1111/dth.14929. Online ahead of print. Retrospective cohort study.
https://doi.org/10.1111/dth.14929
Insights into COVID-19 vaccination in patients with chronic plaque psoriasis on systemic treatments.
Gisondi P, Geat D, Naldi L, Piaserico S.
J Eur Acad Dermatol Venereol. 2021 Mar 1. doi: 10.1111/jdv.17200. Online ahead of print. Commentary.
https://doi.org/10.1111/jdv.17200
SARS-CoV-2 vaccination and immunotherapy in dermatology.
Rodríguez-Villa Lario A, Vega-Díez D, Polo-Rodríguez I.
Actas Dermosifiliogr. 2021 Feb 27:S0001-7310(21)00104-6. doi: 10.1016/j.ad.2021.02.006. Online ahead of print. Spanish, English version to follow. Commentary / review.
https://doi.org/10.1016/j.ad.2021.02.006
Young HIV-positive male patient with severe atopic dermatitis on dupilumab and SARS-CoV-2 infection, a pioneer hypothesis.
Ordóñez-Rubiano MF, Rubiano-Mojica PC, Casas M.
Int J Dermatol. 2021 Feb 28. doi: 10.1111/ijd.15499. Online ahead of print. Case report.
https://doi.org/10.1111/ijd.15499
Intention of COVID-19 vaccination among psoriatic patients compared to immunosuppressed patients with other skin diseases and factors influencing their decision.
Sotiriou E, Bakirtzi K, Papadimitriou I, Paschou E, Vakirlis E, Lallas A, Ioannides D.
Br J Dermatol. 2021 Feb 20. doi: 10.1111/bjd.19882. Online ahead of print. Cross-sectional study.
https://doi.org/10.1111/bjd.19882
The course of COVID-19 infection and prolonged sneezing and nasal congestion in a patient using ixekizumab.
Güder S, Güder H.
Dermatol Ther. 2021 Feb 17. doi: 10.1111/dth.14894. Online ahead of print. Case report.
https://doi.org/10.1111/dth.14894
Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies - A Danish population-based cohort study.
Attauabi M, Seidelin JB, Felding OK, Wewer MD, Vinther Arp LK, Sarikaya MZ, Egeberg A, Vladimirova N, Bendtsen F, Burisch J.
J Autoimmun. 2021 Feb 12;118:102613. doi: 10.1016/j.jaut.2021.102613. Online ahead of print. Population-based cohort study.
https://doi.org/10.1016/j.jaut.2021.102613
European Task Force on Atopic Dermatitis (ETFAD): position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics.
Thyssen JP, Vestergaard C, Barbarot S, de Bruin-Weller MS, Bieber T, Taieb A, Seneschal J, Cork MJ, Paul C, Flohr C, Weidinger S, Trzeciak M, Werfel T, Heratizadeh A, Darsow U, Simon D, Torrelo A, Chernyshov PV, Stalder JF, Gelmetti C, Szalai Z, Svensson Å, von Kobyletzki LB, De Raeve L, Fölster-Holst R, Christen-Zaech S, Jan Hijnen D, Gieler U, Gutermuth J, Bangert C, Spuls PI, Kunz B, Ring J, Wollenberg A, Deleuran M.
J Eur Acad Dermatol Venereol. 2021 Feb 15. doi: 10.1111/jdv.17167. Online ahead of print. Guideline.
https://doi.org/10.1111/jdv.17167
Is SARS-CoV-2 screening test indicated for psoriasis patients candidate to biologic therapy?
Piaserico S, Gisondi P, Cazzaniga S, Girolomoni G, Calzavara-Pinton PG, Naldi L.
J Eur Acad Dermatol Venereol. 2021 Feb 15. doi: 10.1111/jdv.17175. Online ahead of print. Review / commentary.
https://doi.org/10.1111/jdv.17175
A survey of psoriasis patients on biologics during COVID-19: a high-epidemic area experience - Franche Comté, France.
Gallais-Serezal I, Puzenat E, Moreau J, Dresco F, Pelletier F, Nardin C, Aubin F.
Eur J Dermatol. 2021 Feb 12. doi: 10.1684/ejd.2020.3960. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1684/ejd.2020.3960
Concerns and perceptions of patients with psoriatic disease during the COVID-19 pandemic: results from a two-wave survey by the National Psoriasis Foundation.
Gondo GC, Bell SJ, Slayden J, Ullmann G, Blauvelt A.
J Eur Acad Dermatol Venereol. 2021 Feb 15. doi: 10.1111/jdv.17173. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1111/jdv.17173
COVID-19 and biologic therapies in dermatology: seroprevalence survey and severity analysis in a tertiary hospital in Spain.
Barrutia L, Volo V, Ruíz-Sánchez D, Valtueña J, Aguado García A, Manchado López P.
Int J Dermatol. 2021 Feb 9. doi: 10.1111/ijd.15467. Online ahead of print. Cross-sectional study.
https://doi.org/10.1111/ijd.15467
Topical steroids and topical tacrolimus appear safe regarding in relation to the COVID-19 epidemic.
Souaid K, Klejtman T, Kramkimel N, Isnard C, Dupin N, Aractingi S.
Ann Dermatol Venereol. 2021 Jan 8:S0151-9638(21)00003-X. doi: 10.1016/j.annder.2020.12.001. Online ahead of print. Cohort study.
https://doi.org/10.1016/j.annder.2020.12.001
Seroconversion of SARS-CoV-2 infected patients on immunosuppression: a retrospective analysis.
Smith JS, Said JT, Elman SA, Smith CEP, Merola JF.
J Am Acad Dermatol. 2021 Feb 4:S0190-9622(21)00312-1. doi: 10.1016/j.jaad.2021.01.100. Online ahead of print. Cross-sectional study.
https://doi.org/10.1016/j.jaad.2021.01.100
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations.
Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, De Jong E, Garcia-Doval I, Gisondi P, Kaur-Knudsen D, Mahil S, Mälkönen T, Maul JT, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt KM, Sator PG, Schmitt-Egenolf M, Sikora M, Strömer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C.
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):281-317. doi: 10.1111/jdv.16926. Guideline.
https://doi.org/10.1111/jdv.16926
Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond.
Beecker J, Papp KA, Dutz J, Vender RB, Gniadecki R, Cooper C, Gisondi P, Gooderham M, Hong CH, Kirchhof MG, Lynde CW, Maari C, Poulin Y, Puig L.
J Eur Acad Dermatol Venereol. 2021 Feb 3. doi: 10.1111/jdv.17075. Online ahead of print. Review & recommendations.
https://doi.org/10.1111/jdv.17075
COVID-19 incidence in patients with immunomediated inflammatory diseases: Influence of immunosuppressant treatments.
Soldevila-Domenech N, Tío L, Llorente-Onaindia J, Martín-García E, Nebot P, de la Torre R, Gurt A, Maldonado R, Monfort J; Covidmar Study Group.
Front Pharmacol. 2020 Dec 21;11:583260. doi: 10.3389/fphar.2020.583260. eCollection 2020. Cross-sectional study.
https://doi.org/10.3389/fphar.2020.583260
A psoriatic patient-based survey on the understanding of the use of vaccines while on biologics during the COVID-19 pandemic.
Le H, Vender RB.
J Cutan Med Surg. 2021 Jan 27:1203475421991126. doi: 10.1177/1203475421991126. Online ahead of print. Survey.
https://doi.org/10.1177/1203475421991126
Adherence to biological therapy in dermatological patients during the COVID-19 pandemic in Western Sicily.
Tilotta G, Pistone G, Caruso P, Gurreri R, Castelli E, Curiale S, Caputo V, Bongiorno MR.
Int J Dermatol. 2021 Feb;60(2):248-249. doi: 10.1111/ijd.15352. Epub 2020 Dec 8. Cross-sectional study / audit.
https://doi.org/10.1111/ijd.15352
Immunosuppressants, immunomodulators and COVID-19 vaccines: Anticipating patient concerns.
Rick J, Thompson AM, Hsiao JL, Liao W, Shi VY.
J Dermatolog Treat. 2021 Jan 25:1-9. doi: 10.1080/09546634.2021.1880543. Online ahead of print. Commentary.
https://doi.org/10.1080/09546634.2021.1880543
An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology.
Gresham LM, Marzario B, Dutz J, Kirchhof MG.
J Am Acad Dermatol. 2021 Jan 19:S0190-9622(21)00196-1. doi: 10.1016/j.jaad.2021.01.047. Online ahead of print. Review & recommendations.
https://doi.org/10.1016/j.jaad.2021.01.047
Safety of biologics for psoriasis patients during the COVID-19 pandemic: the experience from Wuhan, China.
Zhao L, Du H, Alamgir M, Yang J, Miao X, Jiang B, Xia Y, Lou Y, Wang Y, Shen C, Zhu J, Chung WH, Li Y, Tao J.
Eur J Dermatol. 2020 Dec 1;30(6):738-740. doi: 10.1684/ejd.2020.3908. Cohort study.
https://doi.org/10.1684/ejd.2020.3908
Biologics for atopic diseases: Indication, side effect management, and new developments.
Jappe U, Beckert H, Bergmann KC, Gülsen A, Klimek L, Philipp S, Pickert J, Rauber-Ellinghaus MM, Renz H, Taube C, Treudler R, Wagenmann M, Werfel T, Worm M, Zuberbier T.
Allergol Select. 2021 Jan 5;5:1-25. doi: 10.5414/ALX02197E. eCollection 2021. Commentary.
https://doi.org/10.5414/alx02197e
Immunosuppressive therapies for alopecia areata during COVID-19: A cross-sectional survey study.
Flanagan KE, Pathoulas JT, Walker CJ, Pupo Wiss I, Ellison A, Mesinkovska NA, Senna MM.
Dermatol Ther. 2021 Jan 6. doi: 10.1111/dth.14762. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1111/dth.14762
Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic.
Aşkın Ö, Özkoca D, Uzunçakmak Ü, Kevser T, Serdaroğlu S.
Dermatol Ther. 2021 Jan 6. doi: 10.1111/dth.14746. Online ahead of print. Cross-sectional study.
https://doi.org/10.1111/dth.14746
COVID-19 vaccine and biologics: An impending dilemma.
Hauptman M, Vasic J, Krase J.
J Drugs Dermatol. 2021 Jan 1;20(1):115-114. doi: 10.36849/JDD.2021.5628. Commentary.
https://doi.org/10.36849/jdd.2021.5628
Estimating the susceptibility to SARS-CoV-2 infection with rituximab use for pemphigus vulgaris.
Jafri ZA, Walia S, Ivanic MG, Wu JJ.
J Dermatolog Treat. 2020 Dec 29:1-6. doi: 10.1080/09546634.2020.1870648. Online ahead of print. Review.
https://doi.org/10.1080/09546634.2020.1870648
Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: a retrospective cohort study.
Mahmoudi H, Farid AS, Nili A, Dayani D, Tavakolpour S, Soori T, Teimourpour A, Isazade A, Abedini R, Balighi K, Daneshpazhooh M; Autoimmune Bullous Diseases Research Group.
J Am Acad Dermatol. 2020 Dec 22:S0190-9622(20)33237-0. doi: 10.1016/j.jaad.2020.12.043. Online ahead of print. Retrospective cohort study.
https://doi.org/10.1016/j.jaad.2020.12.043
Risk mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey.
Mahil SK, Yates M, Langan SM, Yiu ZZN, Tsakok T, Dand N, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Bachelez H, Bruce IN, Capon F, Contreras CR, Cope AP, De La Cruz C, Di Meglio P, Gisondi P, Hyrich K, Jullien D, Lambert J, Marzo-Ortega H, McKinnes I, Naldi L, Norton S, Puig L, Sengupta R, Spuls P, Torres T, Warren RB, Waweru H, Weinman J, Griffiths CM, Barker JN, Brown MA, Galloway JB, Smith CH.
Br J Dermatol. 2020 Dec 23. doi: 10.1111/bjd.19755. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1111/bjd.19755
Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: A single-center experience.
Polat Ekinci A, Pehlivan G, Gökalp MO.
Dermatol Ther. 2020 Dec 23. doi: 10.1111/dth.14700. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1111/dth.14700
Safety of secukinumab treatment in COVID-19 affected psoriatic patients.
Mugheddu C, Sanna S, Atzori L, Rongioletti F.
Dermatol Ther. 2020 Dec 27:e14710. doi: 10.1111/dth.14710. Online ahead of print. Case reports.
https://doi.org/10.1111/dth.14710
Hidradenitis suppurativa and adalimumab in the COVID-19 era.
Marzano AV, Moltrasio C, Genovese G, Muratori S, Dapavo P, Fabbrocini G, Patrizi A, Sechi A, Micali G, Pellegrino M, Gisondi P, Dini V, Bianchi L, Fania L, Offidani A, Prignano F, Atzori L, Miraglia E, Cannavò SP, Bettoli V, Stingeni L, Balestri R, Venturini M, Peris K.
Eur J Dermatol. 2020 Dec 18. doi: 10.1684/ejd.2020.3927. Online ahead of print. Report.
https://doi.org/10.1684/ejd.2020.3927
Understanding views of patients on biologics for psoriasis amid the COVID-19 pandemic.
Pandher K, Porter CL, Patel HS, Huang WW, Feldman SR.
J Eur Acad Dermatol Venereol. 2020 Dec 17. doi: 10.1111/jdv.17091. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1111/jdv.17091
COVID-19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases.
Ayhan E, Öztürk M, An İ, Bekçİbaşi M.
Int J Dermatol. 2020 Dec 17. doi: 10.1111/ijd.15379. Online ahead of print. Case reports.
https://doi.org/10.1111/ijd.15379
The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy.
Ciechanowicz P, Dopytalska K, Mikucka-Wituszyńska A, Dźwigała M, Wiszniewski K, Herniczek W, Szymańska E, Walecka I.
J Dermatolog Treat. 2020 Dec 14:1-12. doi: 10.1080/09546634.2020.1861177. Online ahead of print. Cross-sectional study.
https://doi.org/10.1080/09546634.2020.1861177
Biologic therapies, psoriasis, and COVID-19: Our experience at the psoriasis unit of the University of Naples Federico II.
Camela E, Fabbrocini G, Cinelli E, Lauro W, Megna M.
Dermatology. 2020 Dec 9:1-2. doi: 10.1159/000513575. Online ahead of print. Audit / cross-sectional study.
https://doi.org/10.1159/000513575
Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?
Uzuncakmak TK, Özkoca D, Askin O, Kutlubay Z.
Dermatol Ther. 2020 Dec 9:e14647. doi: 10.1111/dth.14647. Online ahead of print. Case series.
https://doi.org/10.1111/dth.14647
The risk of COVID-19 pandemic in patients with moderate to severe plaque psoriasis receiving systemic treatments.
Gisondi P, Bellinato F, Chiricozzi A, Girolomoni G.
Vaccines (Basel). 2020 Dec 2;8(4):E728. doi: 10.3390/vaccines8040728. Review.
https://doi.org/10.3390/vaccines8040728
Association of skin diseases, biological treatment and COVID-19 during the first wave of the pandemic.
Descalzo MA, Garcia-Doval I.
Br J Dermatol. 2020 Dec 4. doi: 10.1111/bjd.19683. Online ahead of print. Commentary.
https://doi.org/10.1111/bjd.19683
Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single centre.
Onsun N, Güneş B, Yabacı A.
Dermatol Ther. 2020 Dec 3:e14623. doi: 10.1111/dth.14623. Online ahead of print. Cohort / registry study.
https://doi.org/10.1111/dth.14623
The COVID-19 pandemic: implications for patients undergoing immunomodulating or immunosuppressive treatments in dermatology.
Reinholz M, French LE, Berking C, Heppt MV.
Eur J Dermatol. 2020 Dec 3. doi: 10.1684/ejd.2020.3775. Online ahead of print. Commentary.
https://doi.org/10.1684/ejd.2020.3775
Impact of COVID-19 pandemic on the continuity of care for dermatologic patients on systemic therapy during the period of strict lockdown.
Alshiyab DM, Al-Qarqaz FA, Muhaidat JM.
Ann Med Surg (Lond). 2020 Dec;60:571-574. doi: 10.1016/j.amsu.2020.11.056. Epub 2020 Nov 25. Cross-sectional & cohort study.
https://doi.org/10.1016/j.amsu.2020.11.056
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: Risk analysis from the PSO-BIO-COVID observational study.
Talamonti M, Galluzzo M, Chiricozzi A, Quaglino P, Fabbrocini G, Gisondi P, Marzano AV, Potenza C, Conti A, Parodi A, Piaserico S, Bardazzi F, Argenziano G, Rongioletti F, Stingeni L, Micali G, Loconsole F, Rossi MT, Bongiorno MR, Feliciani C, Rubegni P, Amerio P, Fargnoli MC, Pigatto P, Savoia P, Nisticò SP, Giustini S, Carugno A, Cannavo' SP, Rech G, Prignano F, Offidani A, Lombardo M, Zalaudek I, Bianchi L, Peris K PSO-BIO-COVID study group.
Expert Opin Biol Ther. 2020 Nov 20. doi: 10.1080/14712598.2021.1853698. Online ahead of print. Cohort / registry study.
https://doi.org/10.1080/14712598.2021.1853698
Management of patients with inflammatory diseases during the COVID-19 pandemic.
Apostolou T, Koutroubakis IE, Manolakopoulos S, Mantzaris G, Rigopoulos D, Triantafyllou K, Vassilopoulos D.
Mediterr J Rheumatol. 2020 Sep 22;31(Suppl 2):295-297. doi: 10.31138/mjr.31.3.295. eCollection 2020 Sep. Review.
https://doi.org/10.31138/mjr.31.3.295
Asymptomatic SARS-CoV2 infection in a patient receiving risankizumab, an inhibitor of IL-23.
Ward M, Gooderham M.
JAAD Case Rep. 2020 Nov 6. doi: 10.1016/j.jdcr.2020.10.032. Online ahead of print. Case report.
https://doi.org/10.1016/j.jdcr.2020.10.032
Does therapy with biological drugs influence COVID-19 infection? Observational, monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone.
Brazzelli V, Isoletta E, Barak O, Barruscotti S, Vassallo C, Giorgini C, Michelerio A, Tomasini CF, Musella V, Klersy C.
Dermatol Ther. 2020 Nov 10:e14516. doi: 10.1111/dth.14516. Online ahead of print. Cohort study.
https://doi.org/10.1111/dth.14516
Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: a Northern Italy experience.
Paolo G, Stefano P, Luigi N, Paolo D, Andrea C, Piergiorgio M, Valerio MA, Federico B, Massimo G, Simone C, Antonio C; Collaborators in the studies of COVID-19 pandemic.
J Allergy Clin Immunol. 2020 Nov 5:S0091-6749(20)31558-X. doi: 10.1016/j.jaci.2020.10.032. Online ahead of print. Multi-centre cohort study.
https://doi.org/10.1016/j.jaci.2020.10.032
If skin is a potential host of SARS-CoV-2, IL-17 antibody could reduce the risk of COVID-19.
Xu Q, Chen L, Li X, Zheng J.
J Am Acad Dermatol. 2020 Nov 4:S0190-9622(20)32905-4. doi: 10.1016/j.jaad.2020.10.084. Online ahead of print. Case series & pathology study.
https://doi.org/10.1016/j.jaad.2020.10.084
Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review.
Sadeghinia A, Daneshpazhooh M.
Dermatol Ther. 2020 Nov 3. doi: 10.1111/dth.14498. Online ahead of print. Review.
https://doi.org/10.1111/dth.14498
COVID-19 in patients with cutaneous immune-mediated diseases in The Netherlands: real-world observational data.
de Wijs LEM, Joustra MM, Olydam JI, Nijsten T, Hijnen DJ.
J Eur Acad Dermatol Venereol. 2020 Nov 1. doi: 10.1111/jdv.17025. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1111/jdv.17025
Letter in reply: Toward a COVID-19 vaccine strategy for pemphigus patients on rituximab.
Waldman RA, Creed M, Sharp K, Adalsteinnson J, Imitola J, Durso T, Lu J.
J Am Acad Dermatol. 2020 Oct 29:S0190-9622(20)32896-6. doi: 10.1016/j.jaad.2020.10.075. Online ahead of print. Commentary.
https://doi.org/10.1016/j.jaad.2020.10.075
Evidence following guidelines: Another COVID-19 paradox.
Heymann WR.
J Am Acad Dermatol. 2020 Oct 29:S0190-9622(20)32891-7. doi: 10.1016/j.jaad.2020.10.070. Online ahead of print. Editorial.
https://doi.org/10.1016/j.jaad.2020.10.070
Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis.
Baniandrés-Rodríguez O, Vilar-Alejo J, Rivera R, Carrascosa JM, Daudén E, Herrera-Acosta E, Sahuquillo-Torralba A, Gómez-García FJ, Nieto-Benito LM, de la Cueva P, López-Estebaranz JL, Belinchón I, Ferrán M, Alsina M, Rodriguez L, Carretero G, García-Donoso C, Ballescá F, Llamas-Velasco M, Herrera-Ceballos E, Botella-Estrada R, Ruiz-Genao DP, Riera-Monroig J, Descalzo MA, García-Doval I; BIOBADADERM Study Group.
J Am Acad Dermatol. 2020 Oct 26:S0190-9622(20)32858-9. doi: 10.1016/j.jaad.2020.10.046. Online ahead of print. Multicentre, prospective cohort study.
https://doi.org/10.1016/j.jaad.2020.10.046
COVID-19 and psoriasis: Recommendation for patients on regular infliximab therapy.
Li S, Zhang S, Wu R, Su Y.
Dermatol Ther. 2020 Oct 30. doi: 10.1111/dth.14472. Online ahead of print. Cohort study.
https://doi.org/10.1111/dth.14472
An evaluation of dermatology patients shielding during the COVID-19 outbreak.
Khan SS, Marshall CL, Stylianou KA, McMullen E, Griffiths CEM, Warren RB, Hunter HJA.
Clin Exp Dermatol. 2020 Oct 24. doi: 10.1111/ced.14489. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1111/ced.14489
Factors associated with adverse COVID-19 outcomes in patients with psoriasis - insights from a global registry-based study.
Mahil SK, Dand N, Mason KJ, Yiu ZZ, Tsakok T, Meynell F, Coker B, McAteer H, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Choon SE, Naldi L, Lambert J, Spuls P, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Di Meglio P, Langan SM, Capon F, Griffiths CE, Barker JN, Smith CH; PsoProtect study group.
J Allergy Clin Immunol. 2020 Oct 16:S0091-6749(20)31413-5. doi: 10.1016/j.jaci.2020.10.007. Online ahead of print. Patient registry study.
https://doi.org/10.1016/j.jaci.2020.10.007
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic.
Hansel K, Zangrilli A, Bianchi L, Peris K, Chiricozzi A, Offidani A, Diotallevi F, Fargnoli MC, Esposito M, Amerio P, Gualdi G, Bianchi L, Stingeni L.
J Eur Acad Dermatol Venereol. 2020 Oct 20. doi: 10.1111/jdv.17003. Online ahead of print. Clinical trial.
https://doi.org/10.1111/jdv.17003
Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis.
Akiyama S, Hamdeh S, Micic D, Sakuraba A.
Ann Rheum Dis. 2020 Oct 13:annrheumdis-2020-218946. doi: 10.1136/annrheumdis-2020-218946. Online ahead of print. Systematic review.
https://doi.org/10.1136/annrheumdis-2020-218946
COVID, biologics, and psoriasis therapy.
Elston DM.
J Am Acad Dermatol. 2020 Sep 10:S0190-9622(20)32589-5. doi: 10.1016/j.jaad.2020.09.005. Online ahead of print. Editorial.
https://doi.org/10.1016/j.jaad.2020.09.005
Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.
Beyzaee AM, Rahmatpour Rokni G, Patil A, Goldust M.
Dermatol Ther. 2020 Oct 13. doi: 10.1111/dth.14405. Online ahead of print. Review.
https://doi.org/10.1111/dth.14405
Impact of COVID-19 on patient-initiated discontinuation of omalizumab in two academic hospital clinics at the University of Toronto.
Seung Kim JH, Georgakopoulos JR, Yeung J.
J Cutan Med Surg. 2020 Sep/Oct;24(5):534-535. doi: 10.1177/1203475420936641. Epub 2020 Jun 17. Retrospective cohort study.
https://doi.org/10.1177/1203475420936641
Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis.
Krueger JG, Murrell DF, Garcet S, Navrazhina K, Lee PC, Muscianisi E, Blauvelt A.
J Allergy Clin Immunol. 2020 Sep 28:S0091-6749(20)31332-4. doi: 10.1016/j.jaci.2020.09.021. Online ahead of print. Research study.
https://doi.org/10.1016/j.jaci.2020.09.021
Effects of lockdown on health of patients with severe atopic dermatitis treated with dupilumab.
Ferrucci SM, Tavecchio S, Favale EM, Angileri L, Riva D, Romagnuolo M, Beretta AE, Marzano AV.
J Eur Acad Dermatol Venereol. 2020 Sep 25. doi: 10.1111/jdv.16955. Online ahead of print. Cohort study.
https://doi.org/10.1111/jdv.16955
COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus.
Chiricozzi A, Garcovich S, Malvaso D, Giovanardi G, Peris K.
Int J Dermatol. 2020 Sep 23. doi: 10.1111/ijd.15209. Online ahead of print. Case report.
https://doi.org/10.1111/ijd.15209
Impacts of COVID-19 on dermatologic practice, disease presentation, and immunomodulator prescriptions.
Leis M, Fleming P, Lynde CW.
J Cutan Med Surg. 2020 Sep 16:1203475420960437. doi: 10.1177/1203475420960437. Online ahead of print. Survey.
https://doi.org/10.1177/1203475420960437
Clinical outcomes of Covid-19 in patients taking tumor necrosis factor inhibitors and/or methotrexate: A multi-center research network study.
Yousaf A, Gayam S, Feldman S, Zinn Z, Kolodney M.
J Am Acad Dermatol. 2020 Sep 11:S0190-9622(20)32593-7. doi: 10.1016/j.jaad.2020.09.009. Online ahead of print. Case-control study.
https://doi.org/10.1016/j.jaad.2020.09.009
Role of dupilumab in approved indications of COVID-19 patient: an efficacy-based nonsystematic critical analysis.
Thangaraju P, Venkatesan N, Sudha TYS, Venkatesan S, Thangaraju E.
SN Compr Clin Med. 2020 Sep 10:1-5. doi: 10.1007/s42399-020-00510-x. Online ahead of print. Review / commentary.
https://doi.org/10.1007/s42399-020-00510-x
COVID and biologics.
Elston DM.
J Am Acad Dermatol. 2020 Sep 11:S0190-9622(20)32595-0. doi: 10.1016/j.jaad.2020.09.010. Online ahead of print. Commentary.
https://doi.org/10.1016/j.jaad.2020.09.010
COVID-19 and systemic therapies in psoriasis: experience of a tertiary hospital in Madrid.
Fulgencio-Barbarin J, Puerta-Peña M, Ortiz-Romero P, García-Donoso C, Rivera-Diaz R.
Int J Dermatol. 2020 Sep 4. doi: 10.1111/ijd.15157. Online ahead of print. Report / audit.
https://doi.org/10.1111/ijd.15157
Nonadherence to treatment and patient-reported outcomes of psoriasis during the COVID-19 epidemic: A web-based survey.
Wang Q, Luo Y, Lv C, Zheng X, Zhu W, Chen X, Shen M, Kuang Y.
Patient Prefer Adherence. 2020 Aug 7;14:1403-1409. doi: 10.2147/PPA.S263843. eCollection 2020. Survey / cross-sectional study.
https://doi.org/10.2147/ppa.s263843
COVID‐19 und Immunregulation – von grundlegenden und translationalen Aspekten zu klinischen Implikationen.
Schön MP, Berking C, Biedermann T, Buhl T, Erpenbeck L, Eyerich K, Eyerich S, Ghoreschi K, Goebeler M, Ludwig RJ, Schäkel K, Schilling B, Schlapbach C, Stary G, von Stebut E, Steinbrink K.
J Dtsch Dermatol Ges. 2020 Aug;18(8):795-809. doi: 10.1111/ddg.14169_g. Review. German.
https://doi.org/10.1111/ddg.14169_g
Systemische Immunsuppression in Zeiten von COVID‐19: Müssen wir umdenken?
Grabbe S, Beissert S, Enk A.
J Dtsch Dermatol Ges. 2020 Aug;18(8):810-814. doi: 10.1111/ddg.14194_g. Review. German.
https://doi.org/10.1111/ddg.14194_g
Association of COVID-19 with skin diseases and relevant biologics: a cross-sectional study using nationwide claim data in South Korea.
Cho SI, Kim YE, Jo SJ.
Br J Dermatol. 2020 Sep 2. doi: 10.1111/bjd.19507. Online ahead of print. Cross-sectional study / claim database analysis.
https://doi.org/10.1111/bjd.19507
Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in psoriasis patients - A meta-estimate of pivotal phase 3 trials relevant to decision-making during the COVID-19 pandemic.
Syed MN, Shah M, Shin DB, Wan MT, Winthrop KL, Gelfand JM.
J Am Acad Dermatol. 2020 Aug 26:S0190-9622(20)32492-0. doi: 10.1016/j.jaad.2020.08.095. Online ahead of print. Trial meta-analysis.
https://doi.org/10.1016/j.jaad.2020.08.095
Management of patients with hidradenitis suppurativa during the Covid-19 pandemic: risk and benefit of immunomodulatory therapy.
Molinelli E, Diotallevi F, Simonetti O, Brisigotti V, Sapigni C, Radi G, Campanati A, Offidani A.
Dermatol Ther. 2020 Aug 29. doi: 10.1111/dth.14256. Online ahead of print. Commentary.
https://doi.org/10.1111/dth.14256
Use of immunosuppressants/immunomodulators in autoimmune/inflammatory dermatologic diseases during COVID-19 pandemic - General recommendation based on available evidence.
De D, Pandhi D.
Indian Dermatol Online J. 2020 Jul 13;11(4):526-533. doi: 10.4103/idoj.IDOJ_414_20. eCollection 2020 Jul-Aug. Review / recommendations.
https://doi.org/10.4103/idoj.idoj_414_20
Effect of immunosuppressive drugs in immune-mediated inflammatory disease during the coronavirus pandemic.
Giuliani F, Gualdi G, Amerio P.
Dermatol Ther. 2020 Aug 23. doi: 10.1111/dth.14204. Online ahead of print. Systematic review.
https://doi.org/10.1111/dth.14204
Lack of evidence for an increased risk of severe COVID-19 in psoriasis patients on biologics: A cohort study from northeast Italy.
Piaserico S, Gisondi P, Cazzaniga S, Naldi L.
Am J Clin Dermatol. 2020 Aug 18. doi: 10.1007/s40257-020-00552-w. Online ahead of print. Cohort study.
https://doi.org/10.1007/s40257-020-00552-w
Coronavirus disease 2019 in a psoriatic patient with concomitant chronic obstructive pulmonary disease under treatment with risankizumab.
Kiss N, Lőrincz K, Medvecz M, Fésűs L, Csuha P, Hermányi Z, Wikonkál NM.
Dermatol Ther. 2020 Aug 14:e14186. doi: 10.1111/dth.14186. Online ahead of print. Case report.
https://doi.org/10.1111/dth.14186
Treatment of pemphigus patients in the COVID-19 era: a specific focus on rituximab.
Mahmoudi H, Tavakolpour S, Nili A, Salehi Farid A, Daneshpazhooh M, Rashidian M.
Dermatol Ther. 2020 Aug 14:e14188. doi: 10.1111/dth.14188. Online ahead of print. Commentary.
https://doi.org/10.1111/dth.14188
Severe COVID-19 outcomes in patients with psoriasis.
Lima XT, Cueva MA, Lopes EM, Alora MB.
J Eur Acad Dermatol Venereol. 2020 Aug 11. doi: 10.1111/jdv.16867. Online ahead of print. Retrospective cohort study.
https://doi.org/10.1111/jdv.16867
Concerns related to the COVID-19 pandemic in adult patients with atopic dermatitis and psoriasis treated with systemic immunomodulatory therapy: a Danish questionnaire survey.
Dyrberg Loft N, Halling AS, Iversen L, Vestergaard C, Deleuran M, Rasmussen MK, Zachariae C, Thyssen JP, Skov L.
J Eur Acad Dermatol Venereol. 2020 Aug 11. doi: 10.1111/jdv.16863. Online ahead of print. Survey.
https://doi.org/10.1111/jdv.16863
Dupilumab in atopic dermatitis, a protocol for SARS-COV 2 infected patients.
Ordóñez-Rubiano MF, Campo I, Casas M.
Dermatol Ther. 2020 Aug 10:e14172. doi: 10.1111/dth.14172. Online ahead of print. Case report / commentary.
https://doi.org/10.1111/dth.14172
Intralesional antigen immunotherapy for warts in the era of COVID-19.
Nofal A, Fawzy MM, Abdelmaksoud A, El-Hawary EE.
J Dermatolog Treat. 2020 Aug 8:1-4. doi: 10.1080/09546634.2020.1808152. Online ahead of print. Commentary / recommendations.
https://doi.org/10.1080/09546634.2020.1808152
Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries.
Gadarowski MB, Balogh EA, Bashyam AM, Feldman SR.
J Dermatolog Treat. 2020 Aug 8:1-17. doi: 10.1080/09546634.2020.1808154. Online ahead of print. Review.
https://doi.org/10.1080/09546634.2020.1808154
Biologic drugs during COVID-19 outbreak.
Montesu MA, Biondi G, Sotgiu G, Sucato F, Satta R.
Int J Dermatol. 2020 Aug 6. doi: 10.1111/ijd.15088. Online ahead of print. Cohort study.
https://doi.org/10.1111/ijd.15088
COVID-19 and immunosuppressive therapy in dermatology.
Schwartz RA, Pradhan S, Murrell DF, Jafferany M, Olisova OY, Lomonosov KM, Lotti T, Goldust M.
Dermatol Ther. 2020 Aug 7:e14140. doi: 10.1111/dth.14140. Online ahead of print. Review / recommendations.
https://doi.org/10.1111/dth.14140
COVID-19 and immunological regulations - from basic and translational aspects to clinical implications.
Schön MP, Berking C, Biedermann T, Buhl T, Erpenbeck L, Eyerich K, Eyerich S, Ghoreschi K, Goebeler M, Ludwig RJ, Schäkel K, Schilling B, Schlapbach C, Stary G, von Stebut E, Steinbrink K.
J Dtsch Dermatol Ges. 2020 Aug 6. doi: 10.1111/ddg.14169. Online ahead of print. Review.
https://doi.org/10.1111/ddg.14169
Severe acute respiratory syndrome coronavirus 2 and the use of biologics in patients with psoriasis.
Ladda M, Lynde C, Fleming P.
J Cutan Med Surg. 2020 Aug 6:1203475420945234. doi: 10.1177/1203475420945234. Online ahead of print. Review.
https://doi.org/10.1177/1203475420945234
Systemic immunosuppression in times of COVID-19: Do we need to rethink our standards?
Grabbe S, Beissert S, Enk A.
J Dtsch Dermatol Ges. 2020 Aug 2. doi: 10.1111/ddg.14194. Online ahead of print. Review.
https://doi.org/10.1111/ddg.14194
Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak.
Veenstra J, Buechler CR, Robinson G, Chapman S, Adelman M, Tisack A, Dimitrion P, Todter E, Kohen L, Lim HW.
J Am Acad Dermatol. 2020 Jul 28:S0190-9622(20)32290-8. doi: 10.1016/j.jaad.2020.07.089. Online ahead of print. Retrospective cohort study.
https://doi.org/10.1016/j.jaad.2020.07.089
Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic.
Kearns DG, Chat VS, Uppal S, Wu JJ.
J Am Acad Dermatol. 2020 Jul 28:S0190-9622(20)32287-8. doi: 10.1016/j.jaad.2020.07.086. Online ahead of print. Trial analysis / commentary.
https://doi.org/10.1016/j.jaad.2020.07.086
Impact of the COVID-19 pandemic on chronic inflammatory dermatoses: Mixed messages regarding the dermatologist's point of view and the patient's concerns.
Fougerousse AC, Maccari F, Reguiai Z, Begon E, Pallure V, Taïeb C, Girard C, Mery-Bossard L.
Acta Derm Venereol. 2020 Jul 31. doi: 10.2340/00015555-3610. Online ahead of print. Commentary.
https://doi.org/10.2340/00015555-3610
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy.
Talamonti M, Galluzzo M, Chiricozzi A, Quaglino P, Fabbrocini G, Gisondi P, Marzano AV, Potenza C, Conti A, Parodi A, Belloni Fortina A, Bardazzi F, Argenziano G, Rongioletti F, Stingeni L, Micali G, Loconsole F, Venturini M, Bongiorno MR, Feliciani C, Rubegni P, Amerio P, Fargnoli MC, Pigatto P, Savoia P, Nisticò SP, Giustini S, Carugno A, Cannavò SP, Rech G, Prignano F, Offidani A, Lombardo M, Zalaudek I, Bianchi L, Peris K; PSO-BIO-COVID study group.
J Eur Acad Dermatol Venereol. 2020 Jul 31. doi: 10.1111/jdv.16841. Online ahead of print. Multicentre observational study.
https://doi.org/10.1111/jdv.16841
COVID-19 and implications for dermatological and allergological diseases.
Buhl T, Beissert S, Gaffal E, Goebeler M, Hertl M, Mauch C, Reich K, Schmidt E, Schön MP, Sticherling M, Sunderkötter C, Traidl-Hoffmann C, Werfel T, Wilsman-Theis D, Worm M.
J Dtsch Dermatol Ges. 2020 Jul 27. doi: 10.1111/ddg.14195. Online ahead of print. Review.
https://doi.org/10.1111/ddg.14195
How infodemic during the COVID-19 outbreak influenced common clinical practice in an Outpatient Service of severe psoriasis.
Sacchelli L, Evangelista V, Di Altobrando A, Lacava R, Rucci P, Rosa S, Patrizi A, Bardazzi F.
Dermatol Ther. 2020 Jul 26:e14065. doi: 10.1111/dth.14065. Online ahead of print. Prospective cohort study.
https://doi.org/10.1111/dth.14065
Chronic inflammatory skin diseases and biologics: what to expect after COVID-19 pandemic?
Megna M, Fabbrocini G, Marasca C.
Int J Dermatol. 2020 Jul 25. doi: 10.1111/ijd.15059. Online ahead of print. Commentary.
https://doi.org/10.1111/ijd.15059
The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies.
Pirro F, Caldarola G, Chiricozzi A, Tambone S, Mariani M, Calabrese L, D'Urso DF, De Simone C, Peris K.
J Dermatolog Treat. 2020 Jul 24:1-14. doi: 10.1080/09546634.2020.1800578. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1080/09546634.2020.1800578
COVID 19 and immunosuppressants: An opinion pool of practising dermatologists of India.
Ray A, Debata I, Agrawal I, Panda M.
Dermatol Ther. 2020 Jul 22:e14036. doi: 10.1111/dth.14036. Online ahead of print. Survey.
https://doi.org/10.1111/dth.14036
Rituximab: a safe therapeutic option during the COVID-19 pandemic?
Di Altobrando A, Patrizi A, Abbenante D, Bardazzi F.
J Dermatolog Treat. 2020 Jul 22:1-3. doi: 10.1080/09546634.2020.1800565. Online ahead of print. Cross-sectional study.
https://doi.org/10.1080/09546634.2020.1800565
A case of severe psoriatic erythroderma with COVID-19.
Ghalamkarpour F, Pourani MR, Abdollahimajd F, Zargari O.
J Dermatolog Treat. 2020 Jul 21:1-11. doi: 10.1080/09546634.2020.1799918. Online ahead of print. Case report.
https://doi.org/10.1080/09546634.2020.1799918
Psoriasis and COVID-19: A narrative review with treatment considerations.
Elmas ÖF, Demirbaş A, Kutlu Ö, Bağcıer F, Metin MS, Özyurt K, Akdeniz N, Atasoy M, Türsen Ü, Lotti T.
Dermatol Ther. 2020 Jun 17:e13858. doi: 10.1111/dth.13858. Online ahead of print.
https://doi.org/10.1111/dth.13858
Treatment discontinuation and rate of disease transmission in psoriasis patients on biologic therapy during the COVID-19 pandemic - A Canadian multicenter retrospective study.
Georgakopoulos JR, Mufti A, Vender R, Yeung J.
J Am Acad Dermatol. 2020 Jul 14. pii: S0190-9622(20)32185-X. doi: 10.1016/j.jaad.2020.07.021. [Epub ahead of print] No abstract available. Retrospective study / case review.
https://doi.org/10.1016/j.jaad.2020.07.021
Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.
Vispi M, Corradin T, Peccianti C, Feci L, Casini L, Pisani C, Fabbroni S, Corsetti P, Croatto M, Pellegrino M.
Dermatol Reports. 2020 Jun 25;12(1):8642. doi: 10.4081/dr.2020.8642. eCollection 2020 Jun 25. Report / audit.
https://doi.org/10.4081/dr.2020.8642
Coronavirus disease 2019 (COVID-19) rash in a psoriatic patient treated with Secukinumab: is there a role for Interleukin 17?
Carugno A, Gambini DM, Raponi F, Vezzoli P, Robustelli Test E, Arosio MEG, Callegaro A, Sena P.
Dermatol Ther. 2020 Jul 12:e14011. doi: 10.1111/dth.14011. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.14011
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?
Talamonti M, Tofani L, Bianchi L, Galluzzo M.
Arch Dermatol Res. 2020 Jul 9. doi: 10.1007/s00403-020-02103-z. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1007/s00403-020-02103-z
More on Covid-19 in immune-mediated inflammatory diseases.
Naldi L, Cazzaniga S.
N Engl J Med. 2020 Jul 10;383. pii: 10.1056/NEJMc2018011#sa1. doi: 10.1056/NEJMc2018011. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1056/NEJMc2018011
Patient´s perspective: psychological burden of the COVID-19 pandemic in 146 psoriatic patients treated with biological drugs and small molecules in real clinical practice.
Rodríguez-Villa Lario A, Vega-Díez D, González-Cañete M, Polo-Rodríguez I, Piteiro-Bermejo AB, Herrero-Fernández M, Arévalo-Serrano J, Trasobares-Marugán L, Medina-Montalvo S.
J Dermatolog Treat. 2020 Jul 9:1-9. doi: 10.1080/09546634.2020.1790485. [Epub ahead of print] No abstract available. Retrospective chart review.
https://doi.org/10.1080/09546634.2020.1790485
How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology.
Jessica Chang TY, Pope JE.
Immunotherapy. 2020 Jul 9. doi: 10.2217/imt-2020-0153. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.2217/imt-2020-0153
Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review.
Seirafianpour F, Sodagar S, Mohammad AP, Panahi P, Mozafarpoor S, Almasi S, Goodarzi A.
Dermatol Ther. 2020 Jul 8. doi: 10.1111/dth.13986. [Epub ahead of print]. Systematic review.
https://doi.org/10.1111/dth.13986
Risk of COVID-19 in dermatologic patients on long-term immunomodulatory therapy.
Holcomb ZE, Santillan MR, Morss-Walton PC, Salian P, Her MJ, Giannotti NM, Kimball AB, Porter ML.
J Am Acad Dermatol. 2020 Jul 1. pii: S0190-9622(20)32099-5. doi: 10.1016/j.jaad.2020.06.999. [Epub ahead of print] No abstract available. Retrospective cross-sectional study.
https://doi.org/10.1016/j.jaad.2020.06.999
The risk of respiratory tract infections in psoriasis patients treated with IL-23-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic.
Syed MN, Shin DB, Wan MT, Winthrop KL, Gelfand JM.
J Am Acad Dermatol. 2020 Jul 2. pii: S0190-9622(20)32115-0. doi: 10.1016/j.jaad.2020.06.1014. [Epub ahead of print] No abstract available. Meta-analysis.
https://doi.org/10.1016/j.jaad.2020.06.1014
Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration.
Ghazawi FM, Lim M, Dutz JP, Kirchhof MG.
Int J Dermatol. 2020 Jul 3. doi: 10.1111/ijd.15028. [Epub ahead of print]. Review.
https://doi.org/10.1111/ijd.15028
COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy versus apremilast in North Spain.
Queiro Silva R, Armesto S, González Vela C, Naharro Fernández C, González-Gay MA.
Dermatol Ther. 2020 Jul 3:e13961. doi: 10.1111/dth.13961. [Epub ahead of print]. Case series.
https://doi.org/10.1111/dth.13961
Global Hidradenitis Suppurativa COVID-19 Registry: A registry to inform data-driven management practices.
Naik HB, Alhusayen R, Frew J, Guilbault S, Ingram JR, Lowes MA, Marzano AV, Paul M, Villumsen B, Yannuzzi CA.
Br J Dermatol. 2020 Jun 29. doi: 10.1111/bjd.19345. [Epub ahead of print]. Research letter.
https://doi.org/10.1111/bjd.19345
Prior treatment with immunosuppressants among COVID-19 inpatients at one hospital in Spain.
Pastor-Nieto MA, Checa-Díaz P, González-Muñoz P, Martín-Fuentes A, Vergara-Sánchez A, Sánchez-Herreros C, Jiménez-Blázquez E, Cabana-Navia R, Martínez-Mariscal J, Cobo-Rodríguez P, Checa-Recio I, Gatica-Ortega ME, Torralba M, De Eusebio-Murillo E.
J Eur Acad Dermatol Venereol. 2020 Jun 28. doi: 10.1111/jdv.16798. [Epub ahead of print]. Cross-sectional study.
https://doi.org/10.1111/jdv.16798
Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: A multicenter study in the Czech Republic.
Rob F, Hugo J, Tivadar S, Boháč P, Gkalpakiotis S, Vargová N, Arenbergerová M, Hercogová J.
J Eur Acad Dermatol Venereol. 2020 Jun 27. doi: 10.1111/jdv.16771. [Epub ahead of print]. Prospective research study.
https://doi.org/10.1111/jdv.16771
COVID-19 and psoriasis: Biologic treatment and challenges.
Ebrahimi A, Sayad B, Rahimi Z.
J Dermatolog Treat. 2020 Jun 29:1-14. doi: 10.1080/09546634.2020.1789051. [Epub ahead of print]. Review.
https://doi.org/10.1080/09546634.2020.1789051
Treatment of psoriasis - unburdened by fear during SARS-CoV2 menace.
Timis TL, Florian IA, Vesa SC, Orasan RI.
J Dermatolog Treat. 2020 Jun 27:1-10. doi: 10.1080/09546634.2020.1788704. [Epub ahead of print]. Review / commentary.
https://doi.org/10.1080/09546634.2020.1788704
Using cyclosporine in the COVID era: an emergent need for caution.
Khurana A, Sethia K.
J Am Acad Dermatol. 2020 Jun 27. pii: S0190-9622(20)32090-9. doi: 10.1016/j.jaad.2020.06.990. [Epub ahead of print]. Commentary.
https://doi.org/10.1016/j.jaad.2020.06.990
COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: A tele-medicine experience.
Shahidi-Dadras M, Abdollahimajd F, Ohadi L, Tabary M, Araghi F, Mozafari N, Toosi P, Dadkhahfar S.
J Dermatolog Treat. 2020 Jun 27:1-7. doi: 10.1080/09546634.2020.1789041. [Epub ahead of print]. Cross-sectional study.
https://doi.org/10.1080/09546634.2020.1789041
COVID-19 infection on IL-23 inhibition.
Wang CJ, Truong AK.
Dermatol Ther. 2020 Jun 25. doi: 10.1111/dth.13893. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13893
Impact of the COVID-19 pandemic on immunomodulatory and immunosuppressive therapies in dermatology: Patient and physician attitudes in Argentina.
Zimman S, Cura MJ, Luna PC, Echeverría CM, Mazzuoccolo LD.
Actas Dermosifiliogr. 2020 Apr 29. pii: S0001-7310(20)30109-5. doi: 10.1016/j.ad.2020.04.004. [Epub ahead of print] English, Spanish. No abstract available. Cross-sectional study.
https://doi.org/10.1016/j.ad.2020.04.004
Organization of biologic therapy during the COVID-19 pandemic based on example of Dermatology Clinic Centre of Postgraduate Medical Education in Warsaw.
Dopytalska K, Mikucka-Wituszyńska A, Ciechanowicz P, Szczerba M, Szymańska E, Walecka I.
J Dermatolog Treat. 2020 Jun 22:1-15. doi: 10.1080/09546634.2020.1782822. [Epub ahead of print]. Report / commentary.
https://doi.org/10.1080/09546634.2020.1782822
Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19.
Fougerousse AC, Perrussel M, Bécherel PA, Begon E, Pallure V, Zaraa I, Chaby G, Parier J, Kemula M, Mery-Bossard L, Poreaux C, Taieb C, Maccari F, Reguiai Z; GEM Resopso.
J Eur Acad Dermatol Venereol. 2020 Jun 21. doi: 10.1111/jdv.16761. [Epub ahead of print]. Multicentre, cross-sectional study.
https://doi.org/10.1111/jdv.16761
International collaboration and rapid harmonization across dermatologic COVID-19 registries.
Freeman EE, McMahon DE, Hruza GJ, Irvine AD, Spuls PI, Smith CH, Mahil SK, Castelo-Soccio L, Cordoro KM, Lara-Corrales I, Naik HB, Alhusayen R, Ingram JR, Feldman SR, Balogh EA, Kappelman MD, Wall D, Meah N, Sinclair R, Beylot-Barry M, Fitzgerald M, French LE, Lim HW, Griffiths CEM, Flohr C.
J Am Acad Dermatol. 2020 Jun 17. pii: S0190-9622(20)31148-8. doi: 10.1016/j.jaad.2020.06.050. [Epub ahead of print] No abstract available. Report / commentary.
https://doi.org/10.1016/j.jaad.2020.06.050
Treatment adherence in psoriatic patients during COVID-19 pandemic: Real-world data from a tertiary hospital in Greece''.
Vakirlis AE, Bakirtzi K, Papadimitriou I, Vrani F, Sideris N, Lallas A, Ioannides D, Sotiriou E.
J Eur Acad Dermatol Venereol. 2020 Jun 18. doi: 10.1111/jdv.16759. [Epub ahead of print]. Survey / observational study.
https://doi.org/10.1111/jdv.16759
Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab.
Facheris P, Valenti M, Pavia G, Gargiulo L, Narcisi A, Costanzo A, Borroni RG.
Int J Dermatol. 2020 Jun 18. doi: 10.1111/ijd.15008. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/ijd.15008
Patients with specific skin disorders who are affected by COVID-19: what do experiences say about management strategies? : A systematic review.
Najar Nobar N, Goodarzi A.
Dermatol Ther. 2020 Jun 18:e13867. doi: 10.1111/dth.13867. [Epub ahead of print]. Systematic review.
https://doi.org/10.1111/dth.13867
Comment on "Psoriasis, COVID-19 and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment".
Farabi B, Bhargava S, Goldust M, Atak MF.
Dermatol Ther. 2020 Jun 14:e13840. doi: 10.1111/dth.13840. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13840
Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic.
Kearns DG, Uppal S, Chat VS, Wu JJ.
J Am Acad Dermatol. 2020 Jun 10. pii: S0190-9622(20)31075-6. doi: 10.1016/j.jaad.2020.06.015. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.1016/j.jaad.2020.06.015
COVID-19 era: A chance to learn something new about monitoring psoriatic patients in biological therapy.
Filippi F, Loi C, Evangelista V, Bardazzi F.
Dermatol Ther. 2020 Jun 10:e13805. doi: 10.1111/dth.13805. [Epub ahead of print] No abstract available. Report / audit.
https://doi.org/10.1111/dth.13805
Biologic agents in psoriasis: our experience during coronavirus infection.
Strippoli D, Barbagallo T, Prestinari F, Russo G, Fantini F.
Int J Dermatol. 2020 Jun 9. doi: 10.1111/ijd.15002. [Epub ahead of print] No abstract available. Cross-sectional study.
https://doi.org/10.1111/ijd.15002
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era.
Galluzzo M, Tofani L, Bianchi L, Talamonti M.
Expert Opin Biol Ther. 2020 Jun 8. doi: 10.1080/14712598.2020.1779217. [Epub ahead of print] No abstract available. Commentary/ cohort study.
https://doi.org/10.1080/14712598.2020.1779217
Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: a single-center real-life experience.
Rossi M, Rovati C, Arisi M, Soglia S, Calzavara-Pinton P.
Dermatol Ther. 2020 Jun 4:e13765. doi: 10.1111/dth.13765. [Epub ahead of print] No abstract available. Case series.
https://doi.org/10.1111/dth.13765
Rate of patient-driven biologic treatment discontinuation during the COVID-19 pandemic in 2 academic hospital clinics at the University of Toronto.
Georgakopoulos JR, Yeung J.
J Cutan Med Surg. 2020 Jun 1:1203475420930226. doi: 10.1177/1203475420930226. [Epub ahead of print] No abstract available. Multicentre retrospective case review.
https://doi.org/10.1177/1203475420930226
Psoriasis, biologic therapy, and the pandemic of the 21st century.
Nogueira M, Vender R, Torres T.
Drugs Context. 2020 May 14;9. pii: 2020-4-10. doi: 10.7573/dic.2020-4-10. eCollection 2020. Editorial.
https://doi.org/10.7573/dic.2020-4-10
Covid-19 infection in psoriasis patients treated with cyclosporin.
Di Lernia V, Goldust M, Feliciani C.
Dermatol Ther. 2020 Jun 1. doi: 10.1111/dth.13739. [Epub ahead of print] No abstract available. Case series.
https://doi.org/10.1111/dth.13739
Psoriasis, COVID-19 and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment.
Magnano M, Balestri R, Bardazzi F, Mazzatenta C, Girardelli CR, Rech G.
Dermatol Ther. 2020 May 30. doi: 10.1111/dth.13706. [Epub ahead of print] No abstract available. Case series.
https://doi.org/10.1111/dth.13706
Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult psoriasis during COVID-19 pandemic.
Melis D, Mugheddu C, Sanna S, Atzori L, Rongioletti F.
Dermatol Ther. 2020 May 30:e13722. doi: 10.1111/dth.13722. [Epub ahead of print]. Case series.
https://doi.org/10.1111/dth.13722
Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab.
Valenti M, Facheris P, Pavia G, Gargiulo L, Borroni RG, Costanzo A, Narcisi A.
Dermatol Ther. 2020 May 30. doi: 10.1111/dth.13708. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13708
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study.
Salvarani C, Bajocchi G, Mancuso P, Galli E, Muratore F, Boiardi L, Catanoso M, Pipitone N, Cassone G, Girolimetto N, Croci S, Cimino L, Gradellini F, Beltrami M, Di Lernia V, Dolci G, Massari M, Marata AM, Costantini M, Giorgi Rossi P.
Ann Rheum Dis. 2020 May 28. pii: annrheumdis-2020-217903. doi: 10.1136/annrheumdis-2020-217903. Epub ahead of print] No abstract available. Cross-sectional study.
https://doi.org/10.1136/annrheumdis-2020-217903
Novel coronavirus disease (COVID-19) and biologic therapy for psoriasis: Successful recovery in two patients after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Brownstone ND, Thibodeaux QG, Reddy VD, Myers BA, Chan SY, Bhutani T, Liao W.
Dermatol Ther (Heidelb). 2020 May 29. doi: 10.1007/s13555-020-00394-8. [Epub ahead of print]. Case reports.
https://doi.org/10.1007/s13555-020-00394-8
Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days.
Karadag AS, Aslan Kayıran M, Lotti T, Wollina U.
Dermatol Ther. 2020 May 27:e13686. doi: 10.1111/dth.13686. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13686
Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic.
Ricardo JW, Lipner SR.
Dermatol Ther. 2020 May 27. doi: 10.1111/dth.13687. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13687
Use of systemic therapies for psoriasis in the COVID-19 era.
Kearns DG, Uppal S, Chat VS, Wu JJ.
J Dermatolog Treat. 2020 May 27:1-14. doi: 10.1080/09546634.2020.1775774. [Epub ahead of print]. Review of guidelines.
https://doi.org/10.1080/09546634.2020.1775774
Preliminary data suggests that biologics in dermatology are not associated with adverse COVID-19 outcomes.
Nassim D, Jfri A, Litvinov IV, Netchiporouk E.
J Cutan Med Surg. 2020 May 25:1203475420929250. doi: 10.1177/1203475420929250. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.1177/1203475420929250
Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient.
Yu Olisova O, Anpilogova EM, Svistunova DA.
Dermatol Ther. 2020 May 24:e13668. doi: 10.1111/dth.13668. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13668
Moderate to severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak.
Giulia R, Alice R, Teresa FM, Paolo D, Simone R.
Dermatol Ther. 2020 May 24. doi: 10.1111/dth.13680. [Epub ahead of print] No abstract available. Retrospective cohort study.
https://doi.org/10.1111/dth.13680
Management of pemphigus in COVID-19 pandemic era; a review article.
Abdollahimajd F, Shahidi-Dadras M, M Robati R, Dadkhahfar S.
Arch Acad Emerg Med . 2020 Apr 18;8(1):e51. eCollection 2020. Review.
http://journals.sbmu.ac.ir/aaem/index.php/AAEM/article/view/663/789
Immunosuppressive agents for dermatological indications in the ongoing COVID 19 pandemic: rationalizing use and clinical applicability.
Khurana A, Saxena S.
Dermatol Ther. 2020 May 21. doi: 10.1111/dth.13639. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13639
Patient-driven discontinuation of dupilumab during the COVID-19 pandemic in two academic hospital clinics at the University of Toronto.
Georgakopoulos JR, Yeung J.
J Cutan Med Surg. 2020 May 20:1203475420930223. doi: 10.1177/1203475420930223. [Epub ahead of print] No abstract available. Retrospective cross-sectional study.
https://doi.org/10.1177/1203475420930223
Is biologic treatment of hidradenitis suppurativa during the COVID-19 pandemic different from psoriasis biologic treatment?
Rosi E, Pimpinelli N, Prignano F.
J Dermatolog Treat. 2020 May 20:1-4. doi: 10.1080/09546634.2020.1771256. [Epub ahead of print] No abstract available. Letter / commentary.
https://doi.org/10.1080/09546634.2020.1771256
COVID-19 and dermatology: A comprehensive guide for dermatologists.
Fahmy DH, El-Amawy HS, El-Samongy MA, Foud AA, Soliman SH, El-Kady A, Farnetani F, Conti A, Zoeir A, Eissa A, Eissa R, Puliatti S, Sighinolfi MC, Rocco B, Pellacani G.
J Eur Acad Dermatol Venereol. 2020 May 19. doi: 10.1111/jdv.16545. [Epub ahead of print]. Review / commentary.
https://doi.org/10.1111/jdv.16545
Active implications for dermatologists in "SARS-CoV-2 era": Personal experience and review of literature.
Campanati A, Brisigotti V, Diotallevi F, D'Agostino GM, Paolinelli M, Radi G, Rizzetto G, Sapigni C, Tagliati C, Offidani A.
J Eur Acad Dermatol Venereol. 2020 May 19. doi: 10.1111/jdv.16646. [Epub ahead of print]. Review / commentary.
https://doi.org/10.1111/jdv.16646
Retrospective analysis of smell and taste disturbances associated with dermatological medications reported to the United States Food and Drug Administration and relevance to COVID-19 infections.
Wang Y, Lipner SR.
J Am Acad Dermatol. 2020 May 17. doi: 10.1016/j.jaad.2020.05.057. [Epub ahead of print] No abstract available.
https://doi.org/10.1016/j.jaad.2020.05.057
Opportunistic virus infections in psoriasis patients: the safer alternative of apremilast.
Armesto S, González Vela C, González López MA.
Dermatol Ther. 2020 May 18:e13618. doi: 10.1111/dth.13618. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13618
Immunosuppressive treatment for systemic sclerosis - therapeutic challenges during the COVID-19 pandemic.
Blicharz L, Czuwara J, Samochocki Z, Goldust M, Olszewska M, Rudnicka L.
Dermatol Ther. 2020 May 19:e13619. doi: 10.1111/dth.13619. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13619
Evidenced-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19.
Galimberti F, McBride J, Cronin M, Li Y, Fox J, Abrouk M, Herbst A, Kirsner RS.
Clin Dermatol. 2020 May 14. doi: 10.1016/j.clindermatol.2020.05.003. [Epub ahead of print]. Review / recommendations.
https://doi.org/10.1016/j.clindermatol.2020.05.003
Safety of dupilumab in atopic patients during COVID-19 outbreak.
Napolitano M, Patruno C, Ruggiero A, Nocerino M, Fabbrocini G.
J Dermatolog Treat. 2020 May 18:1-5. doi: 10.1080/09546634.2020.1771257. [Epub ahead of print] No abstract available. Survey / cross-sectional study.
https://doi.org/10.1080/09546634.2020.1771257
The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic.
Wan MT, Shin DB, Winthrop KL, Gelfand JM.
J Am Acad Dermatol. 2020 May 13. pii: S0190-9622(20)30866-5. doi: 10.1016/j.jaad.2020.05.035. [Epub ahead of print] No abstract available. Meta-analysis.
https://doi.org/10.1016/j.jaad.2020.05.035
COVID-19 knowledge prevents biologics discontinuation: data from an Italian multi-center survey during RED-ZONE declaration.
Bragazzi NL, Riccò M, Pacifico A, Malagoli P; COVID19 Dermatological Task Force, Young Dermatologists Italian Network, Kridin K, Pigatto P, Damiani G.
Dermatol Ther. 2020 May 16:e13508. doi: 10.1111/dth.13508. [Epub ahead of print]. Cross-sectional study / survey.
https://doi.org/10.1111/dth.13508
A survey of psoriasis patients on biologics during COVID-19: a single centre experience.
Burlando M, Carmisciano L, Cozzani E, Parodi A.
J Dermatolog Treat. 2020 May 14:1-3. doi: 10.1080/09546634.2020.1770165. [Epub ahead of print] No abstract available. Survey.
https://doi.org/10.1080/09546634.2020.1770165
Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral centre of Southern Italy.
Marasca C, Ruggiero A, Megna M, Annunziata MC, Fabbrocini G.
J Dermatolog Treat. 2020 May 13:1-3. doi: 10.1080/09546634.2020.1769828. [Epub ahead of print] No abstract available.
https://doi.org/10.1080/09546634.2020.1769828
COVID-19 in an elderly patient treated with secukinumab.
Di Lernia V, Bombonato C, Motolese A.
Dermatol Ther. 2020 May 13:e13580. doi: 10.1111/dth.13580. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13580
Is the coronavirus (COVID-19) pandemic an indication to temporarily modify dermatological management plans?
Shanshal M.
J Drugs Dermatol. 2020 Apr 1;19(4):436. No abstract available. Commentary.
http://jddonline.com/articles/dermatology/S1545961620P0436X
Patient-driven discontinuation of apremilast during the COVID-19 pandemic in two Canadian academic hospital clinics and one community practice.
Georgakopoulos JR, Vender R, Yeung J. Multicenter retrospective study.
J Cutan Med Surg. 2020 May 12:1203475420928382. doi: 10.1177/1203475420928382. [Epub ahead of print]
https://doi.org/10.1177/1203475420928382
COVID-19 and biologics for psoriasis: a high-epidemic area experience - Bergamo, Lombardy, Italy.
Carugno A, Gambini DM, Raponi F, Vezzoli P, Locatelli AGC, Di Mercurio M, Test ER, Sena P.
J Am Acad Dermatol. 2020 May 6. pii: S0190-9622(20)30819-7. doi: 10.1016/j.jaad.2020.04.165. [Epub ahead of print] No abstract available. Case reports & commentary.
https://doi.org/10.1016/j.jaad.2020.04.165
Systemic immunobiological, immunosuppressant and oncologic agents for the treatment of dermatologic diseases during the SARS-Cov-2 (COVID19) pandemic emergency: A quick review for a quick consultation.
Paolino G, Mercuri SR, Bearzi P, Mattozzi C.
Dermatol Ther. 2020 May 8:e13537. doi: 10.1111/dth.13537. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13537
SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab.
Caroppo F, Biolo G, Belloni Fortina A.
J Eur Acad Dermatol Venereol. 2020 May 9. doi: 10.1111/jdv.16619. [Epub ahead of print]. Case report.
https://doi.org/10.1111/jdv.16619
Cyclosporine therapy during the COVID-19 pandemic is not a reason for concern.
Rudnicka L, Goldust M, Glowacka P, Sikora M, Sar-Pomian M, Rakowska A, Samochocki Z, Olszewska M.
J Am Acad Dermatol. 2020 May 3. pii: S0190-9622(20)30775-1. doi: 10.1016/j.jaad.2020.04.153. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.1016/j.jaad.2020.04.153
Clinical considerations for managing dermatology patients on systemic immunosuppressive and/or biologic therapy during COVID-19 pandemic.
Sanchez DP, Kirsner RS, Lev-Tov H.
J Am Acad Dermatol. 2020 May 4. pii: S0190-9622(20)30765-9. doi: 10.1016/j.jaad.2020.04.143. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.1016/j.jaad.2020.04.143
Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs.
Conti A, Lasagni C, Bigi L, Pellacani G.
J Eur Acad Dermatol Venereol. 2020 May 7. doi: 10.1111/jdv.16587. [Epub ahead of print]. Case series.
https://doi.org/10.1111/jdv.16587
Improvement of SARS-CoV2 symptoms following guselkumab injection in a psoriatic patient.
Benhadou F, Del Marmol V.
J Eur Acad Dermatol Venereol. 2020 May 7. doi: 10.1111/jdv.16590. [Epub ahead of print]. Case report.
https://doi.org/10.1111/jdv.16590
Covid-19 in immune-mediated inflammatory diseases - Case series from New York.
Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, Neimann A, Adhikari S, Hudesman D, Scher JU.
N Engl J Med. 2020 Apr 29. doi: 10.1056/NEJMc2009567. [Epub ahead of print] No abstract available. Case series.
https://doi.org/10.1056/NEJMc2009567
Dupilumab and COVID-19: what should we expect?
Patruno C, Stingeni L, Fabbrocini G, Hansel K, Napolitano M.
Dermatol Ther. 2020 May 2. doi: 10.1111/dth.13502. [Epub ahead of print]. Commentary.
https://doi.org/10.1111/dth.13502
SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.
Balestri R, Rech G, Girardelli CR.
J Eur Acad Dermatol Venereol. 2020 May 2. doi: 10.1111/jdv.16571. [Epub ahead of print]. Case report.
https://doi.org/10.1111/jdv.16571
Biologic therapy for psoriasis during the COVID-19 outbreak: the choice is to weigh risks and benefits.
Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I.
Dermatol Ther. 2020 May 1:e13490. doi: 10.1111/dth.13490. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1111/dth.13490
Comment on "Antipsoriatic treatments during COVID-19 outbreak".
Abdelmaksoud A, Goldust M, Vestita M.
Dermatol Ther. 2020 May 1:e13491. doi: 10.1111/dth.13491. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1111/dth.13491
Occurrence of SARS-CoV-2 during mycophenolate mofetil treatment for pemphigus.
Balestri R, Rech G, Girardelli CR.
J Eur Acad Dermatol Venereol. 2020 May 2. doi: 10.1111/jdv.16578. [Epub ahead of print]. Case report / commentary.
https://doi.org/10.1111/jdv.16578
COVID-19: a case for inhibiting IL-17?
Pacha O, Sallman MA, Evans SE.
Nat Rev Immunol. 2020 May 1. doi: 10.1038/s41577-020-0328-z. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1038/s41577-020-0328-z
Biologics increase the risk of SARS- CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration.
Damiani G, Pacifico A, Bragazzi NL, Malagoli P.
Dermatol Ther. 2020 May 1:e13475. doi: 10.1111/dth.13475. [Epub ahead of print]. Cohort study.
https://doi.org/10.1111/dth.13475
Dermatology patients' knowledge and concerns regarding their immunomodulatory medication during the COVID-19 pandemic.
Keeling E, Daly S, McKenna DB.
Dermatol Ther. 2020 May 1:e13488. doi: 10.1111/dth.13488. [Epub ahead of print] No abstract available. Survey.
https://doi.org/10.1111/dth.13488
Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic.
Mahil SK, Yiu ZZN, Mason KJ, Dand N, Coker B, Wall D, Fletcher G, Bosma A, Capon F, Iversen L, Langan SM, Di Meglio P, Musters A, Prieto-Merino D, Tsakok T, Warren RB, Flohr C, Spuls P, Griffiths CEM, Barker J, Irvine AD, Smith CH; Secure-AD, PsoPROTECT study groups.
Br J Dermatol. 2020 Apr 29. doi: 10.1111/bjd.19161. [Epub ahead of print]. Letter/commentary.
https://doi.org/10.1111/bjd.19161
The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience.
Gisondi P, Facheris P, Dapavo P, Piaserico S, Conti A, Naldi L, Cazzaniga S, Malagoli P, Costanzo A.
Br J Dermatol. 2020 Apr 28. doi: 10.1111/bjd.19158. [Epub ahead of print]. Multicentre observational study.
https://doi.org/10.1111/bjd.19158
Biologics for psoriasis in COVID-19 era: what do we know?
Megna M, Napolitano M, Patruno C, Fabbrocini G.
Dermatol Ther. 2020 Apr 27:e13467. doi: 10.1111/dth.13467. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1111/dth.13467
No evidence of increased risk for COVID-19 infection in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy.
Carugno A, Raponi F, Locatelli AG, Vezzoli P, Gambini DM, Di Mercurio M, Robustelli Test E, Sena P.
J Eur Acad Dermatol Venereol. 2020 Apr 27. doi: 10.1111/jdv.16552. [Epub ahead of print]. Case series.
https://doi.org/10.1111/jdv.16552
Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment.
Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G.
J Am Acad Dermatol. 2020 Apr 21. pii: S0190-9622(20)30701-5. doi: 10.1016/j.jaad.2020.04.085. [Epub ahead of print] No abstract available. Cross-sectional study.
https://doi.org/10.1016/j.jaad.2020.04.085
Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports.
Ferrucci S, Romagnuolo M, Angileri L, Berti E, Tavecchio S.
J Eur Acad Dermatol Venereol. 2020 Apr 24. doi: 10.1111/jdv.16527. [Epub ahead of print]. Case reports.
https://doi.org/10.1111/jdv.16527
Immunomodulators and immunosuppressants in the era of SARS-CoV-2 - could laboratory tests be the missing link?
Alpalhão M, Filipe P.
J Dermatolog Treat. 2020 Apr 23:1-8. doi: 10.1080/09546634.2020.1760195. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1080/09546634.2020.1760195
COVID-19 and psoriasis : should we fear for patients treated with biologics?
Amerio P, Prignano F, Giuliani F, Gualdi G.
Dermatol Ther. 2020 Apr 20. doi: 10.1111/dth.13434. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13434
Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?
Di Altobrando A, Patrizi A, Bardazzi F.
J Eur Acad Dermatol Venereol. 2020 Apr 17. doi: 10.1111/jdv.16491. [Epub ahead of print]. Letter.
https://doi.org/10.1111/jdv.16491
Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears.
Megna M, Ruggiero A, Marasca C, Fabbrocini G.
J Dermatolog Treat. 2020 Apr 17:1-5. doi: 10.1080/09546634.2020.1757605. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1080/09546634.2020.1757605
Successful guselkumab treatment in a psoriatic patient affected with Cornelia de Lange Syndrome, and prosecution during the COVID-19 pandemic.
Mugheddu C, Dell'Antonia M, Sanna S, Agosta D, Atzori L, Rongioletti F.
Dermatol Ther. 2020 Apr 18. doi: 10.1111/dth.13433. [Epub ahead of print]. Case report.
https://doi.org/10.1111/dth.13433
Novel coronavirus disease (COVID-19) and biologic therapy in psoriasis: Infection risk and patient counseling in uncertain times.
Brownstone ND, Thibodeaux QG, Reddy VD, Myers BA, Chan SY, Bhutani T, Liao W.
Dermatol Ther (Heidelb). 2020 Apr 16. doi: 10.1007/s13555-020-00377-9. [Epub ahead of print]. Commentary.
https://doi.org/10.1007/s13555-020-00377-9
Psoriasis and psoriatic arthritis: how to manage immunosuppressants in COVID-19 days.
Coletto LA, Favalli EG, Caporali R.
Dermatol Ther. 2020 Apr 14:e13415. doi: 10.1111/dth.13415. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1111/dth.13415
SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.
Messina F, Piaserico S.
J Eur Acad Dermatol Venereol. 2020 Apr 15. doi: 10.1111/jdv.16468. [Epub ahead of print]. Case report.
https://doi.org/10.1111/jdv.16468
Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations.
Blaszczak A, Trinidad JCL, Cartron AM.
J Am Acad Dermatol. 2020 Apr 10. pii: S0190-9622(20)30606-X. doi: 10.1016/j.jaad.2020.04.030. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1016/j.jaad.2020.04.030
The management of biologics in dermatologic patients in the 2019-nCoV era.
Plachouri KM, Georgiou S.
J Dermatolog Treat. 2020 Apr 13:1. doi: 10.1080/09546634.2020.1749544. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1080/09546634.2020.1749544
Reply to "COVID-19, syphilis and biologic therapies for psoriasis and psoriatic arthritis: A word of caution".
Lebwohl M, Rivera-Oyola R, Murrell DF.
J Am Acad Dermatol. 2020 Apr 10. pii: S0190-9622(20)30528-4. doi: 10.1016/j.jaad.2020.03.103. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1016/j.jaad.2020.03.103
Reply to: "Biologics for psoriasis during COVID-19 outbreak".
Murrell DF, Rivera-Oyola R, Lebwohl M.
J Am Acad Dermatol. 2020 Apr 10. pii: S0190-9622(20)30554-5. doi: 10.1016/j.jaad.2020.04.014. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1016/j.jaad.2020.04.014
Biologics for psoriasis during COVID-19 outbreak.
Di Lernia V.
J Am Acad Dermatol. 2020 Apr 10. pii: S0190-9622(20)30543-0. doi: 10.1016/j.jaad.2020.04.004. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1016/j.jaad.2020.04.004
COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australia/New Zealand consensus statement.
Wang C, Rademaker M, Baker C, Foley P.
Australas J Dermatol. 2020 Apr 7. doi: 10.1111/ajd.13313. [Epub ahead of print]. Guideline/consensus statement.
https://doi.org/10.1111/ajd.13313
SECURE-Psoriasis: A de-identified registry of psoriasis patients diagnosed with COVID-19.
Balogh EA, Heron C, Feldman SR, Huang WW.
J Dermatolog Treat. 2020 Apr 8:1-2. doi: 10.1080/09546634.2020.1753996. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1080/09546634.2020.1753996
Biological treatment use amid the COVID-19 era, a close look at the unresolved perplexity.
Shanshal M.
J Dermatolog Treat. 2020 Apr 7:1-9. doi: 10.1080/09546634.2020.1752886. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1080/09546634.2020.1752886
Biologic therapy for psoriasis during the covid-19 outbreak is not a choice.
Bardazzi F, Loi C, Sacchelli L, Di Altobrando A.
J Dermatolog Treat. 2020 Apr 6:1-2. doi: 10.1080/09546634.2020.1749545. [Epub ahead of print] No abstract available.
https://doi.org/10.1080/09546634.2020.1749545
COVID-19, syphilis and biologic therapies for psoriasis and psoriatic arthritis: A word of caution.
Kansal NK.
J Am Acad Dermatol. 2020 Apr 1. pii: S0190-9622(20)30502-8. doi: 10.1016/j.jaad.2020.03.079. [Epub ahead of print] No abstract available.
https://doi.org/10.1016/j.jaad.2020.03.079
Use of systemic immunomodulatory therapies during the coronavirus disease 2019 (COVID-19) pandemic.
Shah P, Zampella JG.
J Am Acad Dermatol. 2020 Mar 31. pii: S0190-9622(20)30478-3. doi: 10.1016/j.jaad.2020.03.056. [Epub ahead of print] No abstract available.
https://doi.org/10.1016/j.jaad.2020.03.056
Comment on "COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action".
Abdelmaksoud A, Goldust M, Vestita M.
Dermatol Ther. 2020 Apr 1:e13360. doi: 10.1111/dth.13360. [Epub ahead of print] No abstract available.
https://doi.org/10.1111/dth.13360
Antipsoriatic treatments during COVID-19 outbreak.
Di Lernia V.
Dermatol Ther. 2020 Mar 29:e13345. doi: 10.1111/dth.13345. [Epub ahead of print] No abstract available.
https://doi.org/10.1111/dth.13345
Biological treatment during COVID-19 outbreak.
Sriwijitalai W, Wiwanitkit V.
J Dermatolog Treat. 2020 Mar 28:1. doi: 10.1080/09546634.2020.1749548. [Epub ahead of print] No abstract available.
https://doi.org/10.1080/09546634.2020.1749548
COVID-19 and immunomodulator/immunosuppressant use in dermatology.
Price KN, Frew JW, Hsiao JL, Shi VY.
J Am Acad Dermatol. 2020 Mar 26. pii: S0190-9622(20)30466-7. doi: 10.1016/j.jaad.2020.03.046. [Epub ahead of print] No abstract available.
https://doi.org/10.1016/j.jaad.2020.03.046
Advice regarding COVID-19 and use of immunomodulators, in patients with severe dermatological diseases.
Rademaker M, Baker C, Foley P, Sullivan J, Wang C.
Australas J Dermatol. 2020 Mar 26. doi: 10.1111/ajd.13295. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/32219857
Should biologics for psoriasis be interrupted in the era of COVID-19?
Lebwohl M, Rivera-Oyola R, Murrell DF.
J Am Acad Dermatol. 2020 Mar 18. pii: S0190-9622(20)30445-X. doi: 10.1016/j.jaad.2020.03.031. [Epub ahead of print]
https://doi.org/10.1016/j.jaad.2020.03.031
Should patients stop their biologic treatment during the COVID-19 pandemic.
Bashyam AM, Feldman SR.
J Dermatolog Treat. 2020 Mar 19:1-2. doi: 10.1080/09546634.2020.1742438. [Epub ahead of print]
https://doi.org/10.1080/09546634.2020.1742438
COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action.
Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I.
Dermatol Ther. 2020 Mar 11:e13298. doi: 10.1111/dth.13298. [Epub ahead of print]
https://doi.org/10.1111/dth.13298
Back to CEBD Coronavirus Dermatology Resource Homepage